Fax: (919) 684-8719
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer
Version of Record online: 19 MAY 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 2, pages 386–391, 15 January 2012
How to Cite
Havrilesky, L. J., Pokrzywinski, R., Revicki, D., Higgins, R. V., Nycum, L. R., Kohler, M. F., Berchuck, A., Myers, E. R. and Secord, A. A. (2012), Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer. Cancer, 118: 386–391. doi: 10.1002/cncr.26199
- Issue online: 5 JAN 2012
- Version of Record online: 19 MAY 2011
- Manuscript Accepted: 29 MAR 2011
- Manuscript Revised: 22 MAR 2011
- Manuscript Received: 14 FEB 2011
- 2Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 61: 2099-2106., , , et al.
- 4A multicenter, randomized, phase II study evaluating the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer [abstract]. Gynecol Oncol. 2010; 116( suppl): A3., , , et al.
- 6New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216., , , et al.
- 14Gold M, Siegel J, Russell L, Weinstein M, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.